SLS NASDAQ
Credit Risk of going bust: lower than 68% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), SELLAS Life Sciences Group, Inc. would be worth roughly what it owes.
Total debt $737K against a stock market value of $2.29B.
Distance to default 7.27 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $658K (short-term plus half of long-term), stock volatility 105.2%; Altman Z'' 16.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
New York, NY 10036
US
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Stergiou Angelos M. | A-Award | 1,065,000 | — | 2026-06-16 |
| Varian John | A-Award | 50,000 | — | 2026-01-07 |
| VAN NOSTRAND ROBERT | A-Award | 50,000 | — | 2026-01-07 |
| SCHEINBERG DAVID A | A-Award | 50,000 | — | 2026-01-07 |
| CICIC DRAGAN | A-Award | 300,000 | — | 2026-01-07 |